By Ed Coghlan
People suffering from migraines received some good news this week.
Amgen has announced positive top-line results for the first phase 3 study of erenumab in episodic migraine. In the study, erenumab demonstrated a statistically significant reduction in monthly migraine days at 12 weeks in patients who experienced between four and 14 migraine days per month.
“People with episodic migraine lose a substantial part of their lives to migraine, and many face intolerable pain and physical impairment, frequently accompanied by a significant disruption of their daily activities. Unfortunately, there are limited preventive treatment options currently available for these patients,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “These positive results, along with the recent chronic migraine results, contribute to the growing body of evidence supporting erenumab as an innovative treatment option for people who are suffering from this debilitating disease.”
Katie Golden, who suffers from migraines and writes extensively on the topic (including on the National Pain Report) sees the latest results from Amgen as very good news that gives migraine sufferers hope that they may soon have a better way of preventing their attacks.
“There has never been a preventative drug developed specifically for migraine patients. We use anti-seizure, depression medications and calcium channel blockers off-label to try to prevent migraine attacks. The last time a new breakthrough in headache medicine occurred was in the 1990s when triptans were introduced, and those are used to stop an attack once it starts.
“For patients, FDA approval for anti-CGRP medications can’t come soon enough. Any reduction in the number of migraine days gives us more time with our family, more time to work and more time to live normally.”
According to Migraine.com almost 5 million in the U.S. experience at least one migraine attack per month while more than 11 million people blame migraines for causing moderate to severe disability. Migraines occur most often in: Women (18 percent of women compared to 6 percent of men)